The total pharmaceutical market in Lebanon was worth US$519mn in 2009 and took up 1.71% of GDP, with per-capita spending on medicines at US$123.4. Prescription drug spending was US$460mn, or 89.7% of the total market. Prescription medicines expenditure is forecast to increase as a proportion of the total market, highlighting a rising trend for healthcare usage. While this can be down to population growth alone, we also believe that access to healthcare services is widening. Patented medicines contributed to 74.8% of the prescription drug market and 67% of the total pharmaceutical sector. Although generic drugs will continue to feature as a small proportion of all pharmaceutical spending, their proportion of the prescription market will rise from 25.2% in 2009 to 30.3% by 2014. Pharmaceutical industry representatives in Lebanon have announced that drug packaging will be redesigned to enable easy confirmation of product authenticity. The move is part of an effort to address the counterfeit medicines that are infiltrating the country. This follows a region-wide crackdown on counterfeit pharmaceuticals through similar measures, with better regulatory provisions promoted as the most effective measure. The Order of Pharmacists (OOP) in Lebanon has stated that drug packaging can easily be forged and that new hologram or high-tech identification tags are to be added to medicine labels to make fakes easier to detect. Public enlightenment campaigns have also been underlined as one of the strategies that will deter further purchases and lower demand for these drugs. The association is also suggesting that pharmacists be positioned at customs and within hospitals to ensure that fake medicines are not unwittingly sold within the national and private healthcare system. Testing laboratories should also be established to ensure that seizures or closures of suspected illegal outlets can be supported with evidence. Imports could also be tested for bioequivalence in this manner, alleviating the reliance on US Food and Drug Administration (FDA)- or European Medicines Agency (EMEA)-derived medicines to ensure product safety.

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Lebanon Pharmaceuticals and Healthcare Report Q2 2010
Published on March 2010
Report Summary
The total pharmaceutical market in Lebanon was worth US$519mn in 2009 and took up 1.71% of GDP, with per-capita spending on
medicines at US$123.4. Prescription drug spending was US$460mn, or 89.7% of the total market. Prescription medicines expenditure
is forecast to increase as a proportion of the total market, highlighting a rising trend for healthcare usage.
While this can be down to population growth alone, we also believe that access to healthcare services is widening. Patented
medicines contributed to 74.8% of the prescription drug market and 67% of the total pharmaceutical sector. Although generic drugs
will continue to feature as a small proportion of all pharmaceutical spending, their proportion of the prescription market will rise from
25.2% in 2009 to 30.3% by 2014.
Pharmaceutical industry representatives in Lebanon have announced that drug packaging will be redesigned to enable easy
confirmation of product authenticity. The move is part of an effort to address the counterfeit medicines that are infiltrating the country.
This follows a region-wide crackdown on counterfeit pharmaceuticals through similar measures, with better regulatory provisions
promoted as the most effective measure.
The Order of Pharmacists (OOP) in Lebanon has stated that drug packaging can easily be forged and that new hologram or high-tech
identification tags are to be added to medicine labels to make fakes easier to detect. Public enlightenment campaigns have also been
underlined as one of the strategies that will deter further purchases and lower demand for these drugs.
The association is also suggesting that pharmacists be positioned at customs and within hospitals to ensure that fake medicines are
not unwittingly sold within the national and private healthcare system. Testing laboratories should also be established to ensure that
seizures or closures of suspected illegal outlets can be supported with evidence. Imports could also be tested for bioequivalence in
this manner, alleviating the reliance on US Food and Drug Administration (FDA)- or European Medicines Agency (EMEA)-derived
medicines to ensure product safety.
Table of Content
Executive Summary ...5
SWOT Analysis...........6
Lebanon Pharmaceuticals And Healthcare Industry SWOT ............... 6
Political SWOT...... 7
Economic SWOT..... 8
Business Environment SWOT..... 9
Business Environment Ratings ..10
Table: Middle East and Africa ' Regional Pharmaceuticals Business Environment Ratings For Q210..... 10
Limits To Potential Returns ..... 11
Risks To Realisation Of Returns ................. 11
Lebanon ' Market Summary .......13
Regulatory Regime...14
Public Sector Procurement ...... 14
Intellectual Property Regime ... 15
IP Shortcomings.... 16
Parallel Imports.... 17
Lebanon Pharmaceuticals and Healthcare Report Q2 2010 Page 1/5

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Counterfeit Drugs . 17
Free Trade Agreements............ 19
Pricing and Reimbursement Issues ............. 20
Industry Developments...............22
Epidemiology........ 22
HIV/AIDS Infections ................ 24
Healthcare Sector . 24
Hospital Sector ..... 25
Healthcare Insurance .............. 26
Healthcare Sector Reforms ...... 27
Retail Pharmacy Sector ........... 28
Regional Developments ........... 28
Clinical Trials....... 29
Medical Devices.... 29
Industry Forecast Scenario .........31
Overall Market Forecast.......... 31
Key Growth Factors ' Industry 32
Key Growth Factors ' Macroeconomic ...... 33
Table: Lebanon ' Economic Activity .......... 35
Prescription Drug Market Forecast............ 36
Patented Drug Market Forecast ................. 37
Generic Drug Market Forecast 38
OTC Medicine Market Forecast ................. 41
Pharmaceutical Trade Forecast ................. 42
Other Healthcare Data Forecasts............... 43
Key Risks to BMI Forecasts ..... 44
Competitive Landscape..............45
Pharmaceuticals Sector ........... 45
Recent Pharmaceutical Industry Developments............. 45
Company Profiles.....47
Indigenous Companies.................. 47
Chalhoub Pharmaceuticals (CHAPHA)...... 47
Alfa Laboratories.. 48
Algorithm.............. 49
Codipha ................ 50
Multinational Companies.............. 51
Pfizer . 51
Novartis ................ 52
Merck & Co .......... 54
Johnson & Johnson.................. 56
Sanofi-Aventis....... 58
GlaxoSmithKline (GSK)........... 60
Abbott Laboratories................. 62
Country Snapshot: Lebanon Demographic Data............64
Section 1: Population............... 64
Table: Demographic Indicators, 2005-2030.................. 64
Section 2: Education And Healthcare......... 65
Table: Education, 2002-2005 .. 65
Table: Vital Statistics, 2005-2030............... 65
BMI Methodology .....66
Lebanon Pharmaceuticals and Healthcare Report Q2 2010 Page 2/5

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
How We Generate Our Pharmaceutical Industry Forecasts .................. 66
Pharmaceutical Business Environment Ratings Methodology ............... 67
Ratings Overview.. 67
Table: Pharmaceutical Business Environment Indicators ................ 68
Weighting.............. 69
Table: Weighting Of Components............... 69
Sources ... 69
Forecast Tables ........70
Lebanon Pharmaceuticals and Healthcare Report Q2 2010 Page 3/5

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Lebanon Pharmaceuticals and Healthcare Report Q2 2010
Product Formats
Please select the product formats and the quantity you require.
Digital Copy--USD 530.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Lebanon Pharmaceuticals and Healthcare Report Q2 2010 Page 4/5

5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Lebanon Pharmaceuticals and Healthcare Report Q2 2010 Page 5/5